Enzo Biochem (NYSE:ENZ) 株価情報

Enzo Biochem

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem Inc

Enzolytics Inc

iShares MSCI New Zealand ETF

ENZON PHARMS INC by Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals Inc

ENZYME ENVIRNMNTL SLTNS by Enzyme Environmental Solutions, Inc.

Enzyme Environmental Solutions Inc

Shares of argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) rose sharply in today's pre-market trading after the company announced the FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and <a href="https://www.benzinga.com/quote/ARGX">chronic inflammatory demyelinating polyneuropathy.</a>
argenx shares jumped 5.1% to $573.88 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) rose 167% to $3.43 in pre-market trading as the company announced strategic term sheet providing prospective liquidity and restructuring of existing agreements to remove corporate guaranteed debt by over $1.2 billion as well as new agreements aimed at driving future growth.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) surged 73.6% to $0.0318 in pre-market trading after jumping 30% on Thursday.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) gained 26.5% to $0.3300 in pre-market after dipping 22% on Thursday.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) rose 26.4% to $0.8198 in pre-market trading. Actelis Networks recently announced it received a new order to modernize Orange County&#8217;s traffic infrastructure.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) rose 25.6% to $5.10 in pre-market trading. Venus Concept announced closing of $1.1 million registered direct offering of common stock priced at-the-market under Nasdaq rules.</li>
<li>DMC Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) gained 21.7% to $7.90 in pre-market trading.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) jumped 19.1% to $5.37 in pre-market trading.</li>
<li>Certara, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) surged 18.1% to $12.41 in pre-market trading after gaining 8% on Thursday.</li>
<li>Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) gained 13.7% to $29.23 in pre-market trading. The stock may be moving up after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>AlTi Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) fell 57.3% to $1.20 in pre-market trading after declining around 6% on Thursday.</li>
<li>cbdMD, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#NYSE">YCBD</a>) shares tumbled 38.9% to $0.1701 in pre-market trading. CbdMD announced shareholder approval of automatic conversion of series a preferred stock and other results from annual meeting.</li>
<li>Nexa Resources S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) fell 32% to $4.01 in today's pre-market trading.</li>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares fell 27.1% to $1.59 in pre-market trading.</li>
<li>Palatin Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PTN#NYSE">PTN</a>) fell 16.8% to $0.3510 in pre-market trading after the company announced it received a NYSE American notice of delisting.</li>
<li>Betterware de México, S.A.P.I. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) shares fell 24% to $8.21 in pre-market trading. Betterware de México will report its first quarter results after the U.S. market close on Thursday, April 24.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) shares dipped 22.3% to $2.20 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 14.9% to $2.35 in pre-market trading.</li>
<li>Costamare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) dipped 14.3% to $7.42 in pre-market trading after falling 5% on Thursday.</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) declined 12.8% to $6.62 in pre-market trading after falling 5% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44734419/top-2-real-estate-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Real Estate Stocks That May Keep You Up At Night This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ALTI

ARGX

ASNS

BOOM

BWMX

CERT

CMRE

INNV

MAZE

MSPR

NEXA

ONVO

RXRX

SLSR

STSS

VERO

YCBD

Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 59.1% to $3.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.9 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares rose 55.48% to $0.33. The company's market cap stands at $6.7 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 26.21% to $0.52. The company's market cap stands at $2.7 million. </li>
<li>Greenwich LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLSI#NASDAQ">GLSI</a>) shares rose 17.71% to $10.9. The market value of their outstanding shares is at $143.2 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares increased by 17.61% to $0.4. The company's market cap stands at $20.9 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) shares increased by 12.8% to $1.65. The market value of their outstanding shares is at $13.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock fell 64.7% to $0.56 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock declined by 46.47% to $0.14. The market value of their outstanding shares is at $1.7 million. </li>
<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) stock declined by 30.51% to $13.99. The company's market cap stands at $1.3 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock decreased by 21.44% to $0.64. The company's market cap stands at $7.4 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 19.17% to $0.07. The market value of their outstanding shares is at $1.7 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) stock decreased by 16.89% to $5.71. The market value of their outstanding shares is at $227.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CRIS

EWTX

GLSI

LUNG

PCSA

PTPI

QNRX

RSLS

SBFM

SYRA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 17.7% to $1.13. The market value of their outstanding shares is at $6.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 16.29% to $3.24. The market value of their outstanding shares is at $8.8 million. As per the press release, Q4 earnings came out today. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 10.48% to $0.55. The market value of their outstanding shares is at $9.3 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 11.2% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 8.9% to $2.51. The company's market cap stands at $3.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.61% to $0.85. The market value of their outstanding shares is at $60.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock declined by 7.83% to $0.34. The market value of their outstanding shares is at $17.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 6.67% to $0.56. The market value of their outstanding shares is at $2.5 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock declined by 6.64% to $4.08. The market value of their outstanding shares is at $84.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BIAF

BNGO

CMPX

CTOR

EVOK

NUTX

PSTV

TLPH

12 Health Care Stocks Moving In Monday's After-Market Session

Shares of Xos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XOS#NASDAQ">XOS</a>) rose sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/XOS">reported 2024 results</a>.
The company reported its 2024 revenue surged to $56 million, compared to $44.5 million in 2023. The company delivered 297 units in 2024, up from 283 units in the previous year. Its GAAP gross margins improved from a negative 2.9% in 2023 to a positive 7.1% in 2024.
Xos shares jumped 9% to $3.75 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 75.3% to $0.1402 in pre-market trading after falling over 22% on Friday.</li>
<li>Citius Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) rose 50.4% to $1.00 in pre-market trading.</li>
<li>Color Star Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) rose 50% to $1.20 in pre-market trading after falling around 5% on Friday.</li>
<li>iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) gained 37.2% to $0.3910 in pre-market trading after dipping more than 17% on Friday.</li>
<li>QuantaSing Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 30.1% to $4.45 in pre-market trading after gaining around 12% on Friday. QuantaSing Group, last week, expanded into pop toys market with strategic acquisition of Letsvan.</li>
<li>Know Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNW#NYSE">KNW</a>) rose 19.2% to $0.8701 in pre-market trading after declining 5% on Friday.</li>
<li>AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) surged 15.5% to $0.1397 in pre-market trading. AIM ImmunoTech, last week, posted upbeat FY 2024 results.</li>
<li>China Yuchai International Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYD#NYSE">CYD</a>) gained 7.7% to $17.96 in pre-market after declining 8% on Friday.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 6.3% to $20.99 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares fell 48.3% to $0.0176 in pre-market trading after dipping 23% on Friday.</li>
<li>Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) fell 37.7% to $7.00 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) fell 19.9% to $9.21 in pre-market trading. The company, last week, reported fourth-quarter financial results and beat its EPS and revenue estimates.</li>
<li>Hillman Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) declined 19.5% to $7.00 in pre-market trading.</li>
<li>Enzo Biochem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) fell 18.7% to $0.35 in pre-market trading. Enzo Biochem announced plans to voluntarily delist its common stock from the new York Stock Exchange.</li>
<li>Arhaus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) dipped 18.3% to $7.00 in pre-market trading after tumbling over 8% on Friday.</li>
<li>NeOnc Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares dipped 17.7% to $14.00 in pre-market trading.</li>
<li>Digital Ally, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGLY#NASDAQ">DGLY</a>) shares tumbled 15.3% to $0.0288 in pre-market trading after falling over 20% on Friday.</li>
<li>CareDx, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) fell 14.3% to $15.40 in today's pre-market trading.</li>
<li>Couchbase, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) shares fell 8.1% to $14.40 in pre-market trading after gaining 7% on Friday.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/03/44534977/jim-cramer-healthpeak-properties-is-a-reasonable-reit-recommends-buying-this-health-care-stock">Jim Cramer: Healthpeak Properties Is A &#8216;Reasonable&#8217; REIT, Recommends Buying This Health Care Stock</a></li>
</ul>

ARHS

BASE

CAPR

CDNA

DGLY

HLMN

ICCT

NTHI

TILE

Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares rose 11.9% to $0.75 during Friday's after-market session. The company's market cap stands at $108.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 10.96% to $0.81. The market value of their outstanding shares is at $2.2 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 10.0% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) stock increased by 9.8% to $4.48. The company's market cap stands at $43.6 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares increased by 9.75% to $4.5. The market value of their outstanding shares is at $165.9 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares rose 8.89% to $0.56. The market value of their outstanding shares is at $48.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares fell 20.5% to $0.02 during Friday's after-market session. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock fell 16.83% to $0.17. The market value of their outstanding shares is at $2.2 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) stock decreased by 14.57% to $0.52. The market value of their outstanding shares is at $13.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares decreased by 14.26% to $0.37. The market value of their outstanding shares is at $19.3 million. </li>
<li>Qualigen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) stock decreased by 13.39% to $3.3. The company's market cap stands at $2.4 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares fell 11.95% to $0.06. The market value of their outstanding shares is at $7.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDSX

BLUE

GCTK

GELS

IPSC

LGMK

MOLN

OCEA

Qualigen Therapeutics, Inc. - Common Stock

QLGN

12 Health Care Stocks Moving In Friday's After-Market Session

News

General

Enzo Biochem To Voluntarily Delist Its Common Stock From The New York Stock Exchange ; Effective On Or About April 17, 2025

WIIM

Enzo Biochem shares are trading higher after the company reported a quarter-over-quarter increase in Q2 sales results.

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock moved upwards by 58.9% to $29.39 during Tuesday's pre-market session. The company's market cap stands at $382.4 million. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) stock increased by 52.68% to $0.13. The market value of their outstanding shares is at $3.5 million. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) stock increased by 20.06% to $28.0. The company's market cap stands at $997.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) shares increased by 18.37% to $0.56. The company's market cap stands at $29.0 million. The company's, Q2 earnings came out yesterday. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares moved upwards by 17.46% to $0.34. The market value of their outstanding shares is at $5.3 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 16.07% to $0.68. The company's market cap stands at $48.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares fell 35.9% to $0.55 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.1 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares decreased by 26.26% to $0.94. The company's market cap stands at $73.1 million. The company's, Q4 earnings came out yesterday. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock fell 22.79% to $0.13. The market value of their outstanding shares is at $2.3 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock declined by 21.56% to $79.5. The market value of their outstanding shares is at $7.5 billion. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock decreased by 18.55% to $2.02. The company's market cap stands at $17.3 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) stock fell 17.69% to $2.7. The company's market cap stands at $365.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXI

HROW

HYPR

SCNX

SRPT

SYRS

VRPX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) stock moved upwards by 15.8% to $27.0 during Monday's after-market session. The market value of their outstanding shares is at $961.5 million. The company's, Q4 earnings came out today. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares moved upwards by 14.7% to $9.75. The company's market cap stands at $31.6 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) stock moved upwards by 14.37% to $3.66. The company's market cap stands at $173.5 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock increased by 8.48% to $0.51. The market value of their outstanding shares is at $26.6 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock increased by 7.93% to $0.62. The market value of their outstanding shares is at $44.1 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock rose 6.31% to $0.47. The market value of their outstanding shares is at $11.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) shares fell 20.5% to $2.02 during Monday's after-market session. The market value of their outstanding shares is at $87.1 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock decreased by 17.93% to $0.14. The market value of their outstanding shares is at $2.5 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares declined by 12.5% to $1.12. The company's market cap stands at $86.7 million. As per the press release, Q4 earnings came out today. </li>
<li>Capstone Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPS#NASDAQ">CAPS</a>) shares declined by 9.4% to $2.7. The company's market cap stands at $3.8 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares decreased by 7.77% to $0.49. The market value of their outstanding shares is at $2.3 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock declined by 7.7% to $0.33. The company's market cap stands at $19.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

CAPS

COEP

ENTO

KYTX

NBTX

SNSE

Earnings

Enzo Biochem Q2 Adjusted EPS $(0.02), Sales $7.3M Up From $6.2M QoQ

Enzo Biochem Receives NYSE Non-Compliance Notice

Enzo Biochem shares are trading lower after the company reported a year-over-year decrease in Q1 revenue results.

Enzo Biochem Q1 EPS $(0.07) Up From $(0.13) YoY; Revenue $2.280M Down From $3.455M YoY

Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) reported quarterly losses of $(0.01) per share. The company reported $7.53 million in sales this quarter.

Enzo Biochem Q4 EPS $(0.01), Sales $7.53M; Cash $52.4M

- Reuters Citing NY Attorney General

Enzo Biochem Ordered To Pay $4.5M For Failing To Protect Patient Data

Enzo Biochem Q3 EPS $(0.06), Sales $8.00M

Shares of PriceSmart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psmt#NASDAQ">PSMT</a>) rose sharply in today&rsquo;s pre-market trading as the company posted better-than-expected <a href="https://www.benzinga.com/quote/PSMT/earnings">earnings for its second quarter</a>.
The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart&rsquo;s quarterly sales came in at $1.29 billion versus expectations of $1.28 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
PriceSmart shares surged 4.6% to $86.90 in pre-market trading.
<h3>Here are some other stocks moving in pre-market trading. 
Gainers</h3>
<ul>
<li>Marin Software Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrin#NASDAQ">MRIN</a>) shares rose 76.1% to $0.5054 in pre-market trading after the company announced upgrades to its Microsoft Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>) advertising integration.</li>
<li>iCoreConnect Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icct#NASDAQ">ICCT</a>) shares rose 46.4% to $1.64 in pre-market trading. iCoreConnect, last month, closed $2,375,000 convertible note financing.</li>
<li>Nano Labs Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/na#NASDAQ">NA</a>) gained 35.1% to $2.00 in pre-market trading. Nano Labs recently filed annual report on Form 20-F for fiscal year 2023.</li>
<li>IN8bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inab#NASDAQ">INAB</a>) shares gained 20.2% to $1.31 in pre-market trading after the company announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell platform.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) gained 18.8% to $0.1069 in pre-market trading after the company reported approval for all proposals at its special meeting of stockholders.</li>
<li>Immuron Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrn#NASDAQ">IMRN</a>) climbed 16.2% to $3.20 in pre-market trading after the company disclosed record sales (unaudited) of Travelan&reg;.</li>
<li>Desktop Metal, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dm#NYSE">DM</a>) shares gained 12.5% to $1.17 in pre-market trading after declining around 4% on Tuesday.</li>
<li>Yatsen Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ysg#NYSE">YSG</a>) rose 11.2% to $3.48 in pre-market trading.</li>
<li>Galmed Pharmaceuticals Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glmd#NASDAQ">GLMD</a>) gained 10.3% to $0.43 in pre-market trading.</li>
</ul>
&nbsp;
<h3>Losers</h3>
&nbsp;
<ul>
<li>Ascent Solar Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asti#NASDAQ">ASTI</a>) declined 50% to $0.1374&nbsp;in pre-market trading after the company announced pricing of a $6 million public offering of shares at $0.14 per share.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) fell 25.8% to $47.50 in pre-market trading after dipping over 35% on Tuesday.</li>
<li>PainReform Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prfx#NASDAQ">PRFX</a>) fell 23.2% to $1.16 in pre-market trading after declining 11% on Tuesday. PainReform recently announced results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to topical post-surgical pain management products available in the market.</li>
<li>Velo3D, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vld#NYSE">VLD</a>) fell 22.4% to $0.3601 in pre-market trading after announcing a proposed public offering.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) shares declined 21.4% to $0.0617 in pre-market trading after jumping over 96% on Tuesday.</li>
<li>Mobile Global Esports Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgam#NASDAQ">MGAM</a>) fell 19.1% to $0.1748 pre-market trading after surging around 78% on Tuesday.</li>
<li>VIA optronics AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/viao#NYSE">VIAO</a>) shares fell 18.8% to $0.7298 in pre-market trading. VIA optronics announced intention to voluntarily delist its ADSs from the New York Stock Exchange.</li>
<li>Biophytis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bpts#NASDAQ">BPTS</a>) fell 10.6% to $0.3522 in pre-market trading. Biophytis shares jumped around 32% on Tuesday after the company reported a year-over-year increase in FY23 EPS results.</li>
<li>Enzo Biochem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enz#NYSE">ENZ</a>) shares fell 7.5% to $1.11 in pre-market trading. Eco Wave.</li>
<li>SMART Global Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgh#NASDAQ">SGH</a>) fell 7.4% to $24.00 pre-market trading. Smart Global posted better-than-expected results for its second quarter. The company saw third-quarter earnings of 30 cents per share, plus or minus 15 cents, versus the 28 cent estimate. The company expects third-quarter revenue of $300 million, plus or minus $25 million, versus the $307.864 million estimate.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38176264/delta-air-lines-pricesmart-and-3-stocks-to-watch-heading-into-wednesday"> Delta Air Lines, PriceSmart And 3 Stocks To Watch Heading Into Wednesday</a>

Penny Stocks

Small Cap

ASTI

BPTS

DXYZ

GLMD

IMRN

INAB

JAGX

MGAM

MRIN

MSFT

PRFX

PSMT

SLNA

VIAO

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Enzo Biochem Q2 EPS $(0.06) Up From $(0.23) YoY, Sales $8.55M

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects HEICO Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hei#NYSE">HEI</a>) to report quarterly earnings at 68 cents per share on revenue of $898.25 million after the closing bell. HEICO shares fell 0.6% to $181.85 in after-hours trading.</li>
<li>EMCOR Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eme#NYSE">EME</a>) said Mark A. Pompa, Executive Vice President and Chief Financial Officer, and R. Kevin Matz, Executive Vice President Shared Services, will step down from their respective positions, effective April 1, 2024. The company named Jason R. Nalbandian as Senior Vice President and CFO. EMCOR shares fell 0.9% to $216.64 in the after-hours trading session.</li>
<li>Analysts expect GEE Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/job#NYSE">JOB</a>) to earn 2 cents per share on revenue of $40.36 million for the latest quarter. The company will release earnings after the markets close. GEE Group shares gained 2.4% to $0.5470 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<ul>
<li>Enzo Biochem, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/enz#NYSE">ENZ</a>) posted a loss of 13 cents per share for the first quarter versus a year-ago loss of 22 cents per share. Enzo Biochem shares gained 4.5% to $1.39 in the after-hours trading session.</li>
<li>Quipt Home Medical Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qipt#NASDAQ">QIPT</a>) is expected to announce its fourth-quarter financial results on Dec. 18, 2023. Quipt Home Medical shares gained 4.6% to $4.54 in the after-hours trading session.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36256926/2u-and-3-other-stocks-under-4-insiders-are-buying"> 2U And 3 Other Stocks Under $4 Insiders Are Buying </a>

QIPT

HEICO, EMCOR Group And 3 Stocks To Watch Heading Into Monday

Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) reported quarterly losses of $(0.13) per share. This is a 40.91 percent increase over losses of $(0.22) per share from the same period last year.

Enzo Biochem Q1 EPS $(0.13) Up From $(0.22) YoY

Press Releases

Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update

Dividends

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend

Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Comments

Enzo Biochem

ニュース

パートナーシップ

ベンジンガ・グローバル